Pharmacyclics (NASDAQ: PCYC) posted its quarterly earnings results on Thursday. The company reported $0.62 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.29 by $0.33. The company had revenue of $57.96 million for the quarter, compared to the consensus estimate of $45.74 million. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was down 25.6% on a year-over-year basis.
Several analysts have also recently commented on the stock. Analysts at JMP Securities initiated coverage on shares of Pharmacyclics in a research note to investors on Friday, February 8th. They set an “outperform” rating and a $104.00 price target on the stock. On a related note, analysts at TheStreet upgraded shares of Pharmacyclics from a “hold” rating to a “buy” rating in a research note to investors on Wednesday, January 30th. Finally, analysts at Credit Suisse initiated coverage on shares of Pharmacyclics in a research note to investors on Tuesday, January 15th. They set an “outperform” rating and a $79.00 price target on the stock.
Seven analysts have rated the stock with a buy rating, and five have issued a hold rating to the company’s stock. The company currently has a consensus rating of “overweight” and an average target price of $83.00.
Pharmacyclics (PCYC) traded up 4.13% on Thursday, hitting $80.21. Pharmacyclics (PCYC) has a 1-year low of $24.04 and a 1-year high of $81.42. The stock’s 50-day moving average is currently $67.64. The company has a market cap of $5.598 billion and a price-to-earnings ratio of 55.66.
Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.